For the roughly 70,000 people in the United States and Europe living with hereditary hemorrhagic telangiectasia (HHT), a typical day can be measured in nosebleeds. The inherited disorder causes fragile, malformed blood vessels that rupture easily, leading to chronic anemia, stroke risk, and a profound lack of treatment options. A new Dutch biotech, RougeTx, is launching with a $58 million Series A to test a biological hypothesis two decades in the making: that stabilizing the cells which wrap around our smallest blood vessels could be the key to stopping the bleeding [WBOC, October 2026].
It is a bet on a specific cell type, the pericyte, and a founder, Franck Lebrin, whose research journey began with a surprising observation about thalidomide. The company's lead candidate, RTX-001, is a small molecule designed to correct pericyte dysfunction and is being advanced toward first-in-human trials for HHT. The substantial, investor-rich round suggests a belief that this biology could open a new therapeutic class, not just for one rare disease but for a range of conditions driven by vascular instability [European Biotechnology Magazine, October 2026].
From a Thalidomide Clue to a Platform Thesis
The scientific origin story traces back to 2010, when Franck Lebrin, then a researcher at the French National Institute of Health and Medical Research (INSERM), was lead author on a study in Nature Medicine. It reported that thalidomide, a drug with a complex history, appeared to reduce the frequency of nosebleeds in a small group of HHT patients [Nature Medicine, April 2010]. The finding was clinically meaningful but biologically puzzling. Lebrin's subsequent research, which continued after he moved to the Leiden University Medical Center (LUMC), aimed to solve that puzzle. The work pointed to pericytes, contractile cells that cling to capillaries and are essential for vascular integrity and maturation.
RougeTx, spun out from LUMC in 2021, is the vehicle for that translated research. The company's lead asset, RTX-001, is a potential once-daily oral therapy designed to restore proper pericyte function and attachment to vessel walls, thereby strengthening fragile vasculature [BioXconomy, October 2026]. Beyond this single candidate, the company is building a small-molecule discovery platform it calls periSCOPE, aimed at systematically targeting pericyte biology [Fierce Biotech, October 2026]. The platform ambition is what likely helped attract a broad syndicate of European life science investors to a still-preclinical company.
The Investor Syndicate and the Path to the Clinic
The $58 million Series A, which also serves as RougeTx's public launch financing, was co-led by BioGeneration Ventures (BGV), Angelini Ventures, and Kurma Partners. The European Investment Bank participated through Angelini Ventures's Aurea co-investment facility, with additional capital from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest, and Kerna Ventures [Angelini Ventures / GlobeNewswire, October 2026]. BGV is noted as the founding investor, indicating early belief in the academic work.
The proceeds are earmarked to fund RTX-001 through Investigational New Drug (IND)-enabling studies and into its first clinical trial in HHT patients. The company has not disclosed a target date for dosing its first patient, but the round size is consistent with funding a program through early-phase clinical readouts. The table below outlines the key investors backing this preclinical bet.
| Investor | Role / Note |
|---|---|
| BioGeneration Ventures (BGV) | Co-lead, founding investor |
| Angelini Ventures | Co-lead |
| Kurma Partners | Co-lead |
| European Investment Bank | Participant via Angelini Ventures's Aurea facility |
| Epidarex Capital | Participant |
| Vesalius Biocapital Partners | Participant |
| ROM Utrecht Region | Participant |
| p53 Invest | Participant |
| Kerna Ventures | Participant |
The High Stakes of First-in-Class Biology
The ambition here is not incremental. RTX-001 aims to be a first-in-class therapy, meaning it would work via a novel mechanism of action compared to any existing drug. For regulators and payers, that novelty is a double-edged sword. It represents uncharted therapeutic potential but also requires a company to educate and prove a new biological pathway. The primary near-term risk for RougeTx is that the elegant pericyte hypothesis, born in academic models, may not translate into a clinically meaningful benefit for patients with HHT. The path is long, expensive, and statistically perilous for any rare disease program.
Furthermore, the competitive landscape, while not crowded with direct pericyte-targeting rivals, is not empty. Other approaches for HHT, including anti-angiogenic therapies repurposed from oncology or devices for embolization, represent the current standard of care. RougeTx's answer to these risks appears to be depth of foundational science and a platform designed to generate backup compounds. The quality and breadth of the investor syndicate, which includes several firms with deep drug development expertise, acts as a signal of rigorous due diligence on the underlying biology.
What a New Standard of Care Could Look Like
The patient population for HHT, also known as Osler-Weber-Rendu syndrome, endures a lifelong burden. The current standard of care is largely supportive and procedural. It can involve frequent blood transfusions for anemia, laser therapies or embolization procedures to cauterize problematic vessels, and the use of drugs like bevacizumab (an intravenous anti-VEGF antibody) that are used off-label with significant side effects and access hurdles [The Manila Times, October 2026]. For many, there is no pharmacotherapy aimed at the root cause of vascular fragility.
RougeTx's bet is that a once-daily oral pill could change that paradigm, moving treatment from reactive intervention to proactive stabilization. Success for RTX-001 would be measured not just in reduced bleeding episodes, but in improved quality of life and reduced need for invasive procedures. The next twelve months will be critical for the company as it moves from platform validation to clinical candidate. Key milestones will include selecting a definitive clinical candidate, completing IND-enabling toxicology studies, and filing regulatory applications to begin a Phase 1 trial. For a field that has seen little therapeutic innovation, the progression of RTX-001 into the clinic will be a closely watched test of whether targeting pericytes is a viable strategy for bringing stability to patients who have had very little.
Sources
- [WBOC, October 2026] RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia | https://www.wboc.com/online_features/press_releases/rougetx-launches-with-58-million-series-a-financing-to-advance-first-in-class-treatment-for/article_5e9112bc-9c5a-5fd5-ba03-b858bface61f.html
- [European Biotechnology Magazine, October 2026] RougeTx launches with $58m to tackle rare bleeding disorder | https://european-biotechnology.com/latest-news/rougetx-launches-with-58m-to-tackle-rare-bleeding-disorder/
- [Nature Medicine, April 2010] Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. | https://www.nature.com/articles/nm.2131
- [BioXconomy, October 2026] RougeTx raises $58m to take on hereditary bleeding disorder | https://www.bioxconomy.com/investment/rougetx-raises-58m-to-take-on-hereditary-bleeding-disorder
- [Fierce Biotech, October 2026] Fierce Biotech Fundraising Tracker 2026 | https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26
- [Angelini Ventures / GlobeNewswire, October 2026] Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia | https://www.globenewswire.com/news-release/2026/10/06/3375142/0/en/angelini-ventures-and-eib-co-lead-58-million-series-a-financing-in-rouge-therapeutics-to-advance-first-in-class-treatment-for-hereditary-hemorrhagic-telangiectasia.html
- [The Manila Times, October 2026] For too long, people living with HHT have faced a serious, lifelong disease with no approved treatment options. | https://www.manilatimes.net